About: Role of Antimicrobial Agents in the Management of Exacerbations of COPD

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Role of Antimicrobial Agents in the Management of Exacerbations of COPD Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Role of Antimicrobial Agents in the Management of Exacerbations of COPD
Creator	Anthonisen, Nicholas Sharma, Sat
Source	Medline; PMC
abstract	Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a common occurrence and characterize the natural history of the disease. Over the past decade, new knowledge has substantially enhanced our understanding of the pathogenesis, outcome and natural history of AECOPD. The exacerbations not only greatly reduce the quality of life of these patients, but also result in hospitalization, respiratory failure, and death. The exacerbations are the major cost drivers in consumption of healthcare resources by COPD patients. Although bacterial infections are the most common etiologic agents, the role of viruses in COPD exacerbations is being increasingly recognized. The efficacy of antimicrobial therapy in acute exacerbations has established a causative role for bacterial infections. Recent molecular typing of sputum isolates further supports the role of bacteria in AECOPD. Isolation of a new strain of Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae was associated with a considerable risk of an exacerbation. Lower airway bacterial colonization in stable patients with COPD instigates airway inflammation, which leads to a protracted self-perpetuating vicious circle of progressive lung damage and disease progression. A significant proportion of patients treated for COPD exacerbation demonstrate incomplete recovery, and frequent exacerbations contribute to decline in lung function. The predictors of poor outcome include advanced age, significant impairment of lung function, poor performance status, comorbid conditions and history of previous frequent exacerbations requiring antibacterials or systemic corticosteroids. These high-risk patients, who are likely to harbor organisms resistant to commonly used antimicrobials, should be identified and treated with antimicrobials with a low potential for failure. An aggressive management approach in complicated exacerbations may reduce costs by reducing healthcare utilization and hospitalization.
has issue date	2012-08-23(xsd:dateTime)
bibo:doi	10.2165/00151829-200504030-00001
bibo:pmid	15987232
has license	no-cc
sha1sum (hex)	4a46f62620d8446cbca1961358ecb328a2d5bfde
schema:url	https://doi.org/10.2165/00151829-200504030-00001
resource representing a document's title	Role of Antimicrobial Agents in the Management of Exacerbations of COPD
has PubMed Central identifier	PMC7100764
has PubMed identifier	15987232
schema:publication	Treat Respir Med
resource representing a document's body	covid:4a46f62620d8446cbca1961358ecb328a2d5bfde#body_text
is schema:about of	named entity 'enhanced' named entity 'Moraxella' named entity 'COPD' named entity 'viruses' named entity 'exacerbations' named entity 'Management' named entity 'vicious circle' named entity 'organisms' named entity 'consumption' named entity 'patients' named entity 'cost' named entity 'patients' named entity 'antimicrobials' named entity 'resistant' named entity 'Lower' named entity 'conditions' named entity 'The' named entity 'Acute exacerbations' named entity 'bacteria' named entity 'sputum' named entity 'bacterial infections' named entity 'systemic corticosteroids' named entity 'AECOPD' named entity 'COPD exacerbations' named entity 'pathogenesis' named entity 'natural history of the disease' named entity 'high-risk' named entity 'advanced' named entity 'typing' named entity 'utilization' named entity 'trimethoprim/sulfamethoxazole' named entity 'placebo' named entity 'serologic testing' named entity 'Greece' named entity 'gemifloxacin' named entity 'Group 0' named entity 'inflammatory response' named entity 'S. pneumoniae' named entity 'amoxicillin/clavulanic acid' named entity 'clarithromycin' named entity 'long-term' named entity 'antimicrobial agent' named entity 'respiratory tract infections' named entity 'Gram-negative bacilli' named entity 'gastrointestinal' named entity 'virulent' named entity 'H. influenzae' named entity 'COPD' named entity 'bacterial culture' named entity 'Trimethoprim/sulfamethoxazole' named entity 'France' named entity 'statistically significant' named entity 'levofloxacin' named entity 'high-risk' named entity 'Inflammatory cytokines' named entity 'pathogen' named entity 'bacterial infections' named entity 'Germany' named entity 'relapse' named entity 'acute exacerbations' named entity 'AECOPD' named entity 'antibodies' named entity 'Clinical studies' named entity 'diabetes' named entity 'poor activity' named entity 'double-blind study' named entity 'viruses' named entity 'pathogens' named entity 'AECOPD' named entity 'reverse transcriptase PCR' named entity 'bronchitis' named entity 'sputum' named entity 'identified patient' named entity 'bacterial strain' named entity 'AECOPD' named entity 'H. influenzae' named entity 'diabetes mellitus' named entity 'dirithromycin' named entity 'COPD' named entity 'serum albumin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software